Ocular melanoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:41 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ocular melanoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Roginolisib for Patients with Advanced Uveal Melanoma https://clinicaltrials.eu/trial/study-of-roginolisib-for-patients-with-advanced-uveal-melanoma/ Wed, 29 Apr 2026 15:03:24 +0000 https://clinicaltrials.eu/trial/study-of-roginolisib-for-patients-with-advanced-uveal-melanoma/ This clinical trial is focused on studying a type of cancer called Advanced Metastatic Ocular/Uveal Melanoma, which is a serious condition affecting the eye. The study will explore the effectiveness of a new treatment called Roginolisib (also known as IOA-244). This medication is being tested to see how well it works compared to other treatments chosen by doctors. The main goal is to understand how Roginolisib affects the survival of patients with this type of melanoma.

Participants in the study will receive either Roginolisib or another treatment selected by their doctor. Roginolisib is taken as a tablet, while other treatments may include medications like Dacarbazine, Opdualag (which contains Nivolumab and Relatlimab), Pembrolizumab, Yervoy (which contains Ipilimumab), or Opdivo (which contains Nivolumab). These treatments are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein.

The study will take place over several months, during which participants will be monitored regularly to assess the effects of the treatment. This includes checking for any changes in the cancer, as well as monitoring overall health and any side effects. The study aims to provide valuable information on the potential benefits of Roginolisib for patients with this challenging form of melanoma.

]]>